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Background: Inspired by the unprecedented historical success of cisplatin, one of the most important research
directions in bioinorganic and medicinal chemistry is dedicated to the development of new anticancer compounds
with the potential to surpass it in antitumor activity, while having lower unwanted side-effects. Therefore, a series of
copper(II) mixed-ligand complexes of the type [Cu(qui)(L)]Y · xH2O (1–6), where Hqui = 2-phenyl-3-hydroxy-4(1H)-
quinolinone, Y = NO3 (1, 3, 5) or BF4 (2, 4, 6), and L = 1,10-phenanthroline (phen) (1, 2),
5-methyl-1,10-phenanthroline (mphen) (3, 4) and bathophenanthroline (bphen) (5, 6), was studied for their in vitro
cytotoxicity against several human cancer cell lines (A549 lung carcinoma, HeLa cervix epitheloid carcinoma, G361
melanoma cells, A2780 ovarian carcinoma, A2780cis cisplatin-resistant ovarian carcinoma, LNCaP androgen-sensitive
prostate adenocarcinoma and THP-1 monocytic leukemia).
Results: The tested complexes displayed a stronger cytotoxic effect against all the cancer cells as compared to
cisplatin. The highest cytotoxicity was found for the complexes 4 (IC50 = 0.36 ± 0.05 μM and 0.56 ± 0.15 μM),
5 (IC50 = 0.66 ± 0.07 μM and 0.73 ± 0.08 μM) and 6 (IC50 = 0.57 ± 0.11 μM and 0.70 ± 0.20 μM) against A2780, and
A2780cis respectively, as compared with the values of 12.0 ± 0.8 μM and 27.0 ± 4.6 μM determined for cisplatin.
Moreover, the tested complexes were much less cytotoxic to primary human hepatocytes than to the cancer cells.
The complexes 5 and 6 exhibited significantly high ability to modulate secretion of the pro-inflammatory cytokines
TNF-α (2873 ± 238 pg/mL and 3284 ± 139 pg/mL for 5, and 6 respectively) and IL-1β (1177 ± 128 pg/mL and 1087 ±
101 pg/mL for 5, and 6 respectively) tested on the lipopolysaccharide (LPS)-stimulated THP-1 cells as compared with
the values of 1173 ± 85 pg/mL and 118.5 ± 4.8 pg/mL found for the commercially used anti-inflammatory drug
prednisone. The ability of the tested complexes to interact with sulfur-containing biomolecules (cysteine and reduced
glutathione) at physiological levels was proved by electrospray-ionization mass spectrometry.
Conclusions: Overall positive results of the biological activity studies revealed that the presented complexes may
represent good candidates for non-platinum anticancer drugs, however, we are aware of the fact that further and
deeper studies mainly in relation to the elucidation of their mechanisms of antiproliferative action will be necessary.
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One of the most important research directions in bioinor-
ganic and medicinal chemistry is dedicated to the develop-
ment of new anticancer compounds with the potential to
be used either in monotherapy or in combination ther-
apy with other approved anticancer drugs as chemosensi-
tizers [1]. Within this scope of research, two main groups
of antitumor active compounds have been developed: (a)
platinum-based complexes derived from cisplatin, oxali-
platin or carboplatin [2], and (b) non-platinum metal
complexes, for example, complexes of ruthenium, gold,
copper and/or silver, which have proved their effectiveness
against a variety of cancer cell lines [3]. Apart from the
potential to achieve relatively high cytotoxicity or re-
markable selectivity against specific cancer cells [4], the
main reason for the use of the non-platinum metal
complexes is the ability to overcome negative side-
effects of cisplatin and other platinum-based anticancer
drugs, e.g. nephrotoxicity, myelosuppression and intrin-
sic and acquired drug-resistance. Suppressions of these
undesirable side-effects could be achieved by applying
metallotherapeutic complexes based on biogenic transi-
tion metals, whose biological functions play an import-
ant role in different essential biochemical pathways, e.g.
cell division, angiogenesis, inflammatory processes, regula-
tion of redox processes, etc. Copper belongs among such
essential trace elements which are important for most
living species [5]. In the human body, it is critical for
multiple biochemical processes, as it plays a fundamen-
tal role in the structure and function of a number of
metalloenzymes. Additionally, it is a redox-active metal
and thus participates in many redox-related transforma-
tions [6]. The influence on the metabolism of reactive
oxygen species (ROS) by copper ions (dominantly the
cuprous ions) has been shown to have an effect on the
development of cancer [7] as well as the potential
manifestation of cytotoxicity. Elevated levels of copper
in blood have been recently proved to induce inflam-
mation in vitro [8] as well as in vivo [9], at least partly,
due to a higher production of ROS. However, this issue
needs further investigation as, on the contrary, some
copper(II) complexes have been shown to act as anti-
inflammatory agents via the inhibition of the NF-κB
activity and attenuation of its target gene expression
[10,11]. Regarding these indispensable roles of copper
for the human organism, it is not surprising that com-
plexes containing copper(II) as the central metal atom
together with a variety of different ligands are one of
the fastest growing groups of non-platinum complexes
with considerable anticancer effects [12-17]. Some of these
complexes, like the mixed-ligand complexes involving
the amino acids and 1,10-phenanthroline-based ligands,
known as CasiopeinasW, received much more attention
than the others due to their remarkable cytotoxicity [18].Recently, we have been engaged in the preparation,
characterization and in vitro cytotoxicity study of
mixed-ligand copper(II) complexes, involving 2-phenyl-
3-hydroxy-4(1H)-quinolinone (Hqui) and 1,10-phenan-
throline derivatives [19,20]. These compounds showed
high in vitro cytotoxic effects against the HOS and
MCF7 human cancer cells, with IC50 ≈ 2–5 μM. We
proved that these complexes interact with DNA via a par-
tial intercalation and act as effective chemical nucleases
under the proper conditions (i.e. oxidative stress and the
presence of reducing agent).
On the basis of the encouraging preliminary results
regarding the in vitro cytotoxicity against the mentioned
human cancer cell lines reported in the case of [Cu(qui)
(L)]Y · xH2O (1–6), where Hqui = 2-phenyl-3-hydroxy-4
(1H)-quinolinone, Y = NO3 (1, 3, 5) or BF4 (2, 4, 6), and
L = 1,10-phenanthroline (phen) (1, 2), 5-methyl-1,10-
phenanthroline (mphen) (3, 4) and bathophenanthroline
(bphen) (5, 6), we decided to extend the spectrum of
human cancer cell lines and to study the in vitro cyto-
toxicity of the complexes against next seven cell lines.
Moreover, we also decided to study the cytotoxicity of
the complexes on the primary culture of human hepato-
cytes and to evaluate their effect on the healthy cells,
with the aim to estimate their therapeutic index. In an
effort to further understand the mechanisms of the cyto-
toxic activity of the reported copper(II) complexes, the
inflammation related processes were also addressed,
since it has been shown that inflammation has an essen-
tial role in tumor progression, and multiple cancers arise
from the sites of infection, chronic irritation and inflam-
mation [21]. To evaluate whether complexes 1–6 have a
rather pro-inflammatory or anti-inflammatory potential,
their ability to modulate the proinflammatory cytokines
TNF-α and IL-1β expressions on the lipopolysaccharide
(LPS)-stimulated macrophage-like cell line THP-1 in vitro
were tested. Additionally, to reveal possible drug-drug inter-
actions that might dramatically influence the applicability
of the studied complexes as drugs, the capability of the
presented complexes to induce major drug-metabolizing
cytochromes P450 was studied. Transcriptional regulation
of these enzymes is controlled mainly by glucocorticoid
receptor (GR) and aryl hydrocarbon receptor (AhR).
Therefore, we studied the effects of the copper(II) com-
plexes 1–6 on the transcriptional activity of GR and AhR,
using stably transfected gene reporter cell lines [22].
Results
Cytotoxicity against human cancer cell lines
In an effort to deeper understand the cytotoxicity and
uncover possible selectivity of the studied complexes,
and in connection with the preliminary data presented
in our recent publications [19,20], we performed in vitro
cytotoxicity testing of complexes 1–6 against a panel of
Table 1 The results of in vitro cytotoxicity of the Cu(II) complexes 1–6
Compounds A549 HeLa G361 A2780 A2780cis LNCaP THP-1 HH1
[Cu(qui)(phen)]NO3 · H2O (1) 2.5 ± 0.4 2.9 ± 0.3 0.82 ± 0.15 0.65 ± 0.28 0.83 ± 0.30 2.4 ± 0.6 2.0 ± 0.1 >10
[Cu(qui)(phen)]BF4 (2) 3.9 ± 1.2 2.7 ± 0.6 0.64 ± 0.20 0.52 ± 0.10 1.7 ± 0.6 1.9 ± 0.6 1.7 ± 0.2 20.4 ± 1.2
[Cu(qui)(mphen)]NO3 · H2O (3) 2.5 ± 0.6 2.6 ± 0.4 0.53 ± 0.22 0.38 ± 0.03 0.78 ± 0.07 2.1 ± 0.6 1.5 ± 0.3 >10
[Cu(qui)(mphen)]BF4 · H2O (4) 2.5 ± 0.6 2.4 ± 1.0 0.53 ± 0.09 0.36 ± 0.05 0.56 ± 0.15 1.5 ± 0.6 1.1 ± 0.4 9.3 ± 0.6
[Cu(qui)(bphen)]NO3 · H2O (5) 1.7 ± 0.3 1.0 ± 0.2 0.96 ± 0.03 0.66 ± 0.07 0.73 ± 0.08 0.74 ± 0.21 0.57 ± 0.08 3.6 ± 0.2
[Cu(qui)(bphen)]BF4 (6) 1.3 ± 0.4 1.3 ± 0.4 0.72 ± 0.06 0.57 ± 0.11 0.70 ± 0.20 0.62 ± 0.08 0.56 ± 0.10 5.3 ± 0.3
cisplatin 25.8 ± 7.1 10.0 ± 2.6 3.4 ± 0.1 12.0 ± 0.8 27.0 ± 4.6 3.8 ± 1.5 2.0a >50
The results of the in vitro cytotoxic study of the Cu(II) complexes 1–6 and cisplatin together with the results of the toxicity to primary human hepatocytes (HH1). Measurements were performed in triplicate, and
cytotoxicity experiments were repeated in three different cell passages. The data are expressed as IC50 ± SD (μM).













Figure 1 Effects of the Cu(II) complexes and prednisone on the
LPS-induced TNF-α secretion. The cells were pre-treated with
complexes 1–6 (0.2 μM), prednisone (0.2 μM) or the vehicle (DMSO)
only. After 1 h of incubation, the inflammatory response was
induced by LPS (except for the control cells). The secretion was
measured 24 h after the LPS adding. The results are expressed as
means ± S.D. for three independent experiments. * significant
difference in comparison with the vehicle-treated cells (p < 0.05),
** significant difference in comparison with the vehicle-treated cells
(p < 0.01), *** significant difference in comparison with the vehicle-
treated cells (p < 0.001), # significant difference in comparison with
the prednisone-treated cells (p < 0.05), ## significant difference in
comparison with the prednisone-treated cells (p < 0.01), + significant
difference in comparison to CuSO4-treated cells (p < 0.05).
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resistant), G361, A549, HeLa, LNCaP, and THP-1) and
compared the obtained results with those belonging to
the widely used anticancer drug cisplatin (Table 1). The
antiproliferative effect of the starting compounds, i.e.
Hqui, Cu(BF4)2 · H2O, Cu(NO3)2 · 3H2O, phen, mphen
and bphen, was assessed on all cancer cell lines and all
the compounds showed insignificant in vitro cytotoxicity,
with IC50 > 50 μM. The significance of individual differ-
ences between the selected groups was evaluated by the
ANOVA method (the level of p < 0.05 was considered
as significant, for further details See Additional file 1:
Figure S1-S7).
Cytotoxicity to human hepatocytes
It is “condicio sin qua non” that an anticancer drug should
be selectively toxic against cancer cells, but not against
healthy, non-transformed cells. Therefore, we examined
the cytotoxicity of the Cu(II) compounds 1–6 in primary
cultures of human hepatocytes (Table 1). The toxicity
against the human hepatic cells was expressed as a mean
value of IC50, calculated from three parallel determina-
tions. The significance of individual differences between
the selected groups was evaluated by the ANOVA method
(the level of p < 0.05 was considered as significant, for
further details See Additional file 1: Figure S8).
In vitro anti-inflammatory activity testing
In addition to testing of toxicity on cellular level, we
decided also to investigate in greater detail the molecular
mechanisms of action of studied complexes using the
cellular model system based on the LPS-activated re-
spiratory burst in phagocytes and its effect on the in-
flammatory cytokine expression. It is well known that
reactive oxygen species (ROS) participate in a series of
different processes causing the intracellular damage,
including the modulation of transcription factor NF-κB
activity (and production of inflammatory cytokines like
TNF-α) and thus represent a link between the oxidative
stress, inflammatory response and apoptosis caused by
the external stimuli (environmental effects, xenobiotics,
etc.) [24,25]. With the knowledge that the tested com-
plexes are able to increase the ROS formation in cell-
free systems, we decided to evaluate their ability to in-
duce the NF-κB-dependent TNF-α and IL-1β expres-
sions in the LPS-activated macrophages. Complexes 1, 2
and 3 slightly increased the secretion of TNF-α (by
factor of ~ 1.25 in comparison to vehicle) (Figure 1).
Similar effect was observed for the cells treated by the
0.1% DMSO solution of CuSO4·5H2O, which increased
the TNF-α expression by the factor of 1.4. On the other
hand, complexes 4, 5 and 6 significantly increased the
production of this cytokine by the factor of 1.6, 1.8, and
2, respectively.A similar situation as for TNF-α was observed in the
case of the IL-1β secretion. The complexes 1, 2, and 3
had practically no influence on the IL-1β expression in
the LPS-activated cells (Figure 2). Compound 4 moder-
ately raised production of IL-1β by the factor of 1.6,
similarly to the solution of CuSO4·5H2O. Compounds 5
and 6, containing bphen as an N-donor ligand, signifi-
cantly increased the amount of IL-1β by the factor of
6.9, and 6.4, respectively. The significance of the differ-
ences between the results was assessed by the ANOVA
analysis, followed by a Tuckey’s post-hoc test for multiple
comparisons, with p < 0.05 considered to be significant.
Transcriptional activity of AhR and GR in gene reporter
assays
Since AhR and GR receptors are master transcriptional
regulators of drug-metabolizing enzymes, we tested the
effects of the copper(II) complexes on the AhR and GR
transcriptional activities in stably transfected human
reporter cell lines AZ-AhR and AZ-GR. These series of
experiments were performed to assess the potential of
the studied compounds to cause the induction of xeno-
biotic metabolizing enzymes. The cells were treated for
24 h with the complexes (<5 μM), model activators
(TCDD, dexamethasone) and vehicle (DMSO). The
Figure 3 Effects of the Cu(II) complexes on the transcriptional activity
seeded on 96-well plates and stabilized for 16 h. Thereafter, the cells were
tetrachlorodibenzo-p-dioxin (TCDD; 10 pM – 10 μM), dexamethasone (DEX;
treatments, the cells were lysed and the luciferase activity was measured. T
a fold induction over the DMSO-treated cells. Experiments were performed
differences between the individual measurements were lower that 5%.
Figure 2 Effects of the Cu(II) complexes and prednisone on the
LPS-induced IL-1β secretion. The cells were pre-treated with
complexes 1–6 (0.2 μM), prednisone (0.2 μM) or the vehicle (DMSO)
only. After 1 h of incubation, the inflammatory response was
induced by LPS (except for the control cells). The secretion was
measured 24 h after the LPS adding. The results are expressed as
means ± S.D. for three independent experiments. *** significant
difference in comparison with the vehicle-treated cells (p < 0.001),
### significant difference in comparison with the prednisone-treated
cells (p < 0.001), +++ significant difference in comparison with the
CuSO4-treated cells (p < 0.001).
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by TCDD and DEX in the AZ-AhR and AZ-GR cells,
respectively (Figure 3).
Interactions with sulfur-containing biomolecules
In an effort to mechanistically describe the interactions
of three representative complexes 1, 3 and 5 with differ-
ent relevant biomolecules (amino acids and small pep-
tides) and to identify the biologically active species
possibly responsible for the high cytotoxicity of the
tested compounds, the electrospray-ionization mass-
spectrometry (ESI-MS) measurements were carried out.
The positive ionization mode was used with the solution
of two most important sulfur-containing low-molecular
biogenic compounds, i.e. cysteine (Cys) and reduced
glutathione (GSH), containing the physiological levels of
cysteine (290 μM) and reduced glutathione (6 μM) [26].
In order to find a possible effect of the concentration on
the type and intensity of the ionic species formed by the
interaction with cysteine and glutathione, two different
concentrations (1 μM and 7 μM) of the tested com-
plexes were used. The corresponding interaction systems
contained two freshly prepared working solutions: (a)
the solution of cysteine (the final concentration of
290 μM) and reduced glutathione (final conc. 6 μM)of AhR and GR. AZ-GR (Panel A) and/or AZ-AHR (Panel A) cells were
treated for 24 h with the tested complexes (10 nM – 5 μM), 2,3,7,8-
10 pM – 100 nM) and/or vehicle (DMSO; 0.1% V/V). After the
he data are mean from triplicate measurements and are expressed as
in two different passages of the AZ-AHR and AZ-GR cells. The
Trávníček et al. Chemistry Central Journal 2012, 6:160 Page 6 of 12
http://journal.chemistrycentral.com/content/6/1/160dissolved in an aqueous solution of 50 mM ammonium
acetate in water, and (b) the solutions of 1, 3 and 5 in
methanol, to give the final concentration of 1 μM or
7 μM. All the ESI-MS spectra were compared to the
control, containing only the solution of cysteine (the
final concentration of 290 μM) and reduced glutathione
(the final concentration of 6 μM) in the equibalanced
mixture of 50 mM ammonium acetate in water and
methanol. The resulting interacting solutions were mea-
sured immediately after the preparation and visually
controlled for further 2 hours. The immediately mixed
interacting systems were slightly opalescent during the
measurements of ESI-MS spectra and white precipitate
formed during the next two hours, leaving the colorless
or slightly yellowish transparent supernatant. The ESI-
MS experiments revealed diverse combinations of spe-
cies in all the measured systems (see Figure 4). In theFigure 4 ESI-MS spectra of interacting systems, involving the Cu(II) co
the mixture of physiological levels of cysteine (290 μM) and glutathione (6
interacting system containing cysteine (290 μM) + glutathione (6 μM) + com
methanol (1:1, v/v) immediately after the preparation (b; green line); the in
complex 5 (7 μM) in the mixture of 50 mM ammonium acetate and metha
(i.e. lines b and c) showing the appearance of the specific ions, connected
exchange mechanism (for more details See Section Interactions with sulfurcontrol sample, containing only the mixture of cysteine
and reduced glutathione, the following ions were identified:
(see Figure 4, red line (a); m/z, [the corresponding pseudo-
molecular ion]+): 122.06, [Cys +H]+; 143.98, [Cys +Na]+;
240.96, [Cys-S-S-Cys +H]+; 262.96, [Cys-S-S-Cys +Na]+;
308.09, [GSH + H]+; 330.09, [GSH + Na]+; and 427.01,
[GS-S-Cys + H]+. An example showing the interactions
of the most cytotoxic complex 5 (in the final concentra-
tion of 1 μM) with the mixture of cysteine and reduced
glutathione is depicted in Figure 4, green line (b). The
ESI-MS spectrum of this system confirmed the redox-
based interactions, as can be seen from the appearance
of the peaks associated with the oxidation of cysteine
and glutathione and their intermolecular disulphides: (m/z,
[the corresponding pseudomolecular ion]+): 427.07, [GS-S-
Cys +H]+; 449.02, [GS-S-Cys +Na]+; 480.84, [GS-S-Cys +
H + 3H2O]
+; 502.67, [GS-S-Cys +Na + 3H2O]
+. Moreover,mplexes, L-cysteine, and reduced glutathione. ESI-MS spectrum of
μM) in 50 mM ammonium acetate in water (a; red line); the
plex 5 (1 μM) in the mixture of 50 mM ammonium acetate and
teracting system containing cysteine (290 μM) + glutathione (6 μM) +
nol (1 : 1, v/v) immediately after the preparation (c; blue line), both
either with the oxidative mechanism of the interaction or the ligand-
-containing biomolecules).
Figure 5 The resistance factors of Cu(II) complexes, expressed
as the IC50(A2780cis)/IC50(A2780) ratios. The graphical view of
the IC50(A2780cis)/IC50(A2780) ratios calculated from the obtained
IC50 (μM) values of the in vitro cytotoxicity for complexes 1 and 3–6,
and cisplatin against the ovarian carcinoma (A2780) and ovarian
carcinoma cisplatin resistant (A2780cis) human cancer cell lines. The
symbol (***) denotes the statistically significant differences
(p < 0.001) between the values of IC50(A2780cis) and IC50(A2780).
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copper(II) ion from the complex 5 with cysteine was identi-
fied as well: (m/z, [corresponding pseudomolecular ion]+):
238.05, [Cu +Cys +H + 3H2O]
+, which was accompanied
by the release of the N-donor ligand (bphen), as proved
by the detection of the peaks observed at 333.19,
[bphen + H]+ and 664.40, [2bphen + H]+ (see Figure 4,
green line (b)). In an effort to uncover the influence of
the studied complexes concentrations on the type and
intensity of the ionic species, we performed the same
experiments, described in the spectrum labeled as (b),
however, with the concentration of complex 5 of 7 μM
(see Figure 4, blue line (c)). In this interaction system,
the considerable decrease in the intensities of the peaks
corresponding to the disulphide-species, formed by the
oxidation of cysteine and glutathione, i.e. [GS-S-Cys +
H + 3H2O]
+ and [GS-S-Cys + Na + 3H2O]
+, was observed.
Moreover, a new peak associated with the presence of the
[Cu(bphen)2]
+ species was observed at m/z 727.17 (see
Figure 4, blue line (c)). On the other hand, the inten-
sities of the peaks corresponding to the ionic species
[bphen + H]+ at m/z 333.19, [2bphen + H]+ at m/z
664.46, and [2bphen +Na]+ at m/z 687.21 were increased
considerably. The identical interaction patterns and simi-
lar ionic species were also found in the ESI-MS spectra of
the interacting systems, involving both complex 1 and 3.
Discussion
The results of in vitro cytotoxicity studies against the
panel of seven human cancer cell lines uncovered the
significant differences of the IC50 ± SD (μM) values (as
presented in Table 1) between all the tested complexes
1–6 and the reference drug cisplatin against the A549,
HeLa, G361, A2780 and A2780cis cell lines. Moreover,
all the tested complexes showed remarkable selectivity
towards the G361 and A2780 cell lines, but importantly
also towards cisplatin-resistant A2780cis cell line, almost
in all the cases with sub-micromolar IC50 values. Add-
itionally, it can be said that the calculated IC50(A2780cis)/
IC50(A2780) ratio is practically two times lower for 5 and
6 in comparison with cisplatin (Figure 5). The cytotoxic
effects for complexes 4, 5 and 6 towards the LNCaP and
THP-1 cell lines were identified to be significantly better
than those for cisplatin, making them the most effective
antiproliferative agents within the tested compounds.
As can be seen, the studied complexes may be divided
into two groups differing in the counter ion only, i.e. ei-
ther the NO3
- (1, 3, and 5) or BF4
- (2, 4, and 6) counter
ion was used. Taking into consideration the same com-
plex cation and different anions, there are three pairs of
such complexes which can be compared, i.e. 1 vs. 2, 3
vs. 4, and 5 vs. 6. The comparison of the cytotoxic effect
within these pairs leads to the conclusion that the type
of anionic species does not have an effect on theantiproliferative action, because there was found no statis-
tical significance between the IC50 values of the corre-
sponding pairs against all the studied cell lines. Moreover,
the lipophilicity of the heterocyclic N-donor co-ligands
(phen <mphen < bphen) in the studied complexes corre-
lates well with the cytotoxicity in the case of the A549,
HeLa, LNCaP and THP-1 cell lines, i.e. the increase in
lipophilicity of the ligands is accompanied by the decrease
in the IC50 values. These observations are in an agreement
with the recent reports on significant toxicity of copper(II)
mixed-ligand complexes [12,27] involving the heterocyclic
N-donor ligands of the 1,10-phenanthroline-type.
The importance of the results achieved on a panel of
human cancer cell lines has been also emphasized by the
results on primary culture of human hepatocytes. Consid-
erably lower cellular toxicity of the studied complexes to
primary human hepatocytes was identified and demon-
strated by the values of IC50, which were approximately an
order of magnitude higher in most cases than those repre-
senting the cytotoxicity to the human cancer cell lines
(Table 1). Hence, the in vitro cytotoxicity profile of the
tested compounds is promising in terms of potential
therapeutic use.
Although the most important mechanism, i.e. a direct
effect of the studied Cu(II) complexes onto DNA, in-
volving intercalation of the complexes into DNA struc-
ture and initiation of the oxidation stress leading to the
oxidative DNA damage, has been already discussed in
our previous paper [19,20], the next mechanism helping
damage cell homeostase and contributing to cytotoxic
effect of the studied Cu(II) complexes has been
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testing revealed significant augmentation of TNF-α cyto-
kine expression induced by complexes 4, 5 and 6 could
be caused by a higher pro-oxidant ability of these com-
pounds. The graph in Figure 1 shows that the increase
in lipophilicity of the N-donor co-ligands (phen <
mphen < bphen, i.e. 1, 2 < 3, 4 < 5, 6) leads to the in-
crease in the TNF-α secretion. This is supposedly caused
by better penetration of lipophilic compounds to the
cells. The type of counter ion (NO3
- vs. BF4
–) played a sig-
nificant role in the TNF-α production. The complexes 2,
4, and 6 involving the BF4
– counter anion non-
significantly increased the amount of the cytokine in
comparison with the NO3
– counter anion complexes (1,
3, and 5 respectively). The level of the secreted TNF-α
correlated with the rate of cytotoxicity well. It is pos-
sible, that observed cytotoxic effect is caused, at least in
part, by activation of TNF receptor 1 (TNFR1) by
secreted TNF-α leading to induction of apoptosis.
In the case of the IL-1β cytokine, the reason why com-
plexes 5 and 6 increase its secretion so high may be
related to the fact that they probably activate the
NLRP3/NALP3 inflammasome via a higher ROS produc-
tion or directly via the activation of the inflammasome
itself. This enzyme complex is highly regulated by ROS
and reacts on this danger signal by processing pro-IL-1β
into active IL-1β [28]. A similar effect to compounds 5
and 6 was described for doxorubicin and daunorubicin
[29]. The mentioned anticancer drugs were able to in-
crease the production of IL-1β in the LPS-stimulated
(not in unstimulated) murine bone marrow-derived
macrophages via the NLRP3/NALP3 inflammasome acti-
vation. But recent studies have indicated that higher pro-
duction of IL-1β is connected with tumor progression
[30,31]. Because commonly used anticancer drugs doxo-
rubicin and daunorubicin show similar effect as herein
tested Cu(II) complexes, the particular role of IL-1β dur-
ing cancerogenesis should be elucidated in vivo in the
presence of these chemical agents. The effect of a differ-
ent counter ion was not observed for the IL-1β
secretion.
In connection with cytotoxic tests on healthy human
hepatocytes, which revealed a relatively advantageous
ratio between an effective concentration in relation to
cancer cell lines and toxic concentration in relation to
human hepatocytes, successful experiments were per-
formed to assess the potential of the studied compounds
to cause the induction of xenobiotic metabolizing
enzymes as one of the substantive parameters determin-
ing the applicability of compounds as potential drugs.
Gene reporter assays, assessing the transcriptional activ-
ity of AhR and GR in transfected cells proved that the
tested compounds did not induce the luciferase activity
in AZ-GR, but in the highest concentration of thecomplexes, the luciferase activity was decreased, prob-
ably due to the toxic effects of complexes (Figure 3).
The luciferase activity in the AZ-AHR cells was slightly
increased by complexes 1–4, but the induction was
about 1% of the potency achieved by TCDD (Figure 3).
Overall, the tested compounds may be considered in-
active towards GR and AhR signaling pathways.
On the basis of the results following from the ESI-MS
experiments, it was clearly shown that complexes 1, 3
and 5 are able to interact with the sulfur-containing bio-
genic biomolecules (cysteine and reduced glutathione) at
the physiological levels. These interactions may be asso-
ciated with at least two simultaneously proceeding
mechanisms. The first mechanism is based on the oxida-
tion of biomolecules, leading to the formation of disul-
phide bonds between cysteine and glutathione, while the
second one is related to the direct reaction of copper
species with cysteine or glutathione. It is evident, that
the quinolinonate ligand is the first ligand in the corre-
sponding complex undergoing the ligand-exchange,
while the second bidentate N-donor ligand (a phenan-
throline derivative, e.g. phen, mphen, or bphen) is
involved in the dynamic equilibrium, enabling it to par-
ticipate in the formation of much more complicated
complex species, as was documented by the peaks in the
mass spectra of interacting systems, involving complexes
1, 3, and 5, corresponding to the [CuL2]
+ ion, where L
stands for a 1,10-phenanthroline derivative. In an effort
to find a relationship between the described mechanisms
of interactions and the observed biological activity of the
studied complexes, we performed a comparison of our
findings with the published results regarding the
mechanisms of action of copper(II) complexes involving
the 1,10-phenanthroline (phen) moiety in combination
with other types of ligands. The theories, presented in
the literature [32-34], may lead to the conclusion that
the [CuL2]
+ ion, where L stands for a 1,10-phenanthro-
line derivative, can be considered as biologically relevant
species which is able to reversibly bind onto the poly-
nucleotide chain of DNA. Moreover, these ions are able
to participate in the Fenton’s reaction in proper condi-
tions and produce a whole set of reactive oxygen species
in situ [35], leading to the oxidative damage of nucleo-
bases, oxidation-related mutagenesis, or cleavage of the
polynucleotide backbone. The above-mentioned mech-
anism of the cytotoxic action of copper(II)-phen com-
plexes is in agreement with our findings observed in the
interaction study of complexes 1, 3 and 5 with a mixture
of sulfur-containing low-molecular biogenic compounds,
cysteine and glutathione, under physiological conditions.
Conclusions
A series of mixed-ligand copper(II) complexes of the type
[Cu(qui)(L)]Y · xH2O (1–6), where Hqui = 2-phenyl-3-
Figure 6 Schematic representations of the complex cations in
[Cu(qui)(L)]Y•xH2O (1–6). Schematic representations of the
complex cations in [Cu(qui)(L)]Y · xH2O (1–6), where Hqui = 2-phenyl-
3-hydroxy-4(1H)-quinolinone, Y = NO3 (1, 3, 5) or BF4 (2, 4, 6).
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4, 6), and L = 1,10-phenanthroline (phen) (1, 2), 5-
methyl-1,10-phenanthroline (mphen) (3, 4) and batho-
phenanthroline (bphen) (5, 6), was studied for their
in vitro cytotoxicity against seven human cancer cell
lines (A549, HeLa, G361, A2780, A2780cis, LNCaP and
THP-1). The tested complexes displayed a stronger
cytotoxic effect against all the cancer cell lines as com-
pared to cisplatin. The best results were achieved for
complexes 4, 5 and 6 against A2780 and A2780cis, with
the IC50 values in the range of 0.4 – 0.7 μM. On the
other hand, the tested complexes were much less cyto-
toxic to primary human hepatocytes than to the cancer
cells showing the ratio between the effective concentra-
tion against the cancer cells and the toxic concentration
to primary human hepatocytes up to 1:40 (for complex
3). Moreover, complexes 5 and 6 exhibited a signifi-
cantly higher ability to modulate the secretion of the
pro-inflammatory cytokines TNF-α and IL-1β tested on
the lipopolysaccharide (LPS)-stimulated THP-1 cells.
The pro-inflammatory activity of the Cu(II) complexes
represents next of possible pathways influencing cell
processes leading to manifestation of cytotoxicity of the
studied compounds. The ability of the tested complexes
to interact with sulfur-containing biomolecules (cyst-
eine and reduced glutathione) at physiological levels
was proved by ESI-MS experiments and the results led
to the proposal of several possible mechanisms of direct
interaction with biomolecules in relation to the cyto-
toxic action. Overall positive results of the biological
activity studies revealed that the presented complexes
may represent good candidates for non-platinum antic-
ancer drugs, however, we are aware of the fact that
further and deeper studies mainly in connection with
the elucidation of their mechanisms of antiproliferative
action and acute toxicity will be necessary.
Methods
Chemistry
All chemicals and solvents were purchased from com-
mercial sources (Sigma-Aldrich Co., Acros Organics Co.,
Lachema Co., Fluka Co.) and were used as received. The
preparation and characterization of complexes 1, 3, 5
and 2, 4, 6 were already reported by our group [19,20].
The copper(II) mixed-ligand complexes of the types [Cu
(qui)(phen)]NO3 · H2O (1), [Cu(qui)(phen)]BF4 (2), [Cu
(qui)(mphen)]NO3 · H2O (3), [Cu(qui)(mphen)]BF4 · H2O
(4), [Cu(qui)(bphen)]NO3 · H2O (5) and [Cu(qui)(bphen)]
BF4 (6) (qui = 2-phenyl-3-hydroxy-4(1H)-quinolinonate
anion, phen = 1,10-phenanthroline, mphen = 5-methyl-1,
10-phenanthroline, bphen = bathophenanthroline) (Figure 6)
were prepared and fully characterized previously [19,20].
Complexes 1–6 are soluble in polar solvents and their
mixed water solutions with dimethylformamide (DMF),dimethyl sulfoxide (DMSO) or methanol (MeOH) were
used in the tests of biological activities and interaction
studies.
In vitro cytotoxicity testing
Human cancer cell lines A2780 (ovarian carcinoma;
ECACC No. 93112517), A2780cis (ovarian carcinoma
cisplatin-resistant; ECACC No. 93112519), G361 (malig-
nant melanoma; ECACC No. 88030401), A549 (lung car-
cinoma; ECACC No. 86012804), HeLa (cervix epitheloid
carcinoma; ECACC No. 93021013), LNCaP (androgen-
sensitive human prostate adenocarcinoma; ECACC No.
89110211) and THP-1 (human monocytic leukemia;
ECACC No. 88081201) were purchased from the Euro-
pean Collection of Cell Cultures (ECACC). The culture
medium and conditions were according to the ECACC
instructions. Experiments were performed using the cell
passage ranging from 5th to 30th. The cells were main-
tained at 37°C and 5% CO2 in a humidified incubator.
The human cancer cell lines A2780, A2780cis, G361,
A549, HeLa and LNCaP were treated with the tested
compounds (applied in the volume of 200 μL and in the
concentrations ranging from 0.01 μM to 50 μM, unless
their solubility was lower) for 24 h, using 96-well culture
plates. In parallel, the cells were treated with vehicle
(DMF; 0.1%, v/v) and Triton X-100 (1%, v/v) to assess
the minimal (i.e. positive control) and maximal (i.e.
negative control) cell damage, respectively. The MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
assay was measured spectrophotometrically at 540 nm
(TECAN, Schoeller Instruments LLC) [36]. The data were
expressed as the percentage of viability, when 100% and 0%
represent the treatments with DMF, and Triton X-100,
respectively. The data were acquired from three inde-
pendent experiments (conducted in triplicate) using
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mean IC50 ± SD (μM) values together with their stand-
ard deviations, calculated from viability curves. The
obtained IC50 values were evaluated by the ANOVA
analysis incorporated within the QC Expert program
package [37].
The human monocytic leukemia cell line THP-1 (float-
ing monocytes, 500 000 cells/mL) was incubated in
100 μL of the serum-free RPMI 1640 medium and
seeded into 96-well plates in triplicate at 37°C. Measure-
ments were taken 24 h after the treatment with the
tested compounds in the concentrations of 6–0.074 μM
dissolved in dimethylsulfoxide (DMSO). Viability was
measured by the WST-1 test [Cell Proliferation Reagent
WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetra-
zolium]-1,3-benzene disulfonate) was obtained from Roche
(Mannheim, Germany)] according to manufacturer’s man-
ual. The amount of created formazan (which correlates to
the number of metabolically active cells in the culture) was
calculated as a percentage of the control cells, which were
treated only with DMSO and was set-up as 100% [38]. The
IC50 values were calculated from viability curves by soft-
ware GraphPad Prism 5.02 (GraphPad Software Inc., San
Diego, CA). The data are presented as mean IC50 ± SD
(μM) values of three independent experiments.
Primary cultures of human hepatocytes
Human hepatocytes were isolated from a liver tissue,
resected from a multiorgan donor. A tissue acquisition
protocol was in accordance with the requirements issued
by an Ethical committee at the Faculty Hospital Olo-
mouc in the Czech Republic. Human hepatocytes were
isolated by two-step collagenase perfusion and the cells
were plated on a collagen-coated culture dishes using
cell density of 14 × 104 cells/cm2 [39]. The culture
medium was Williams and HAMs F-12 (1 : 1) supple-
mented with penicillin, streptomycin, ascorbic acid, lino-
leic acid, holo-transferin, ethanolamine, glucagon,
insulin, dexamethasone, pyruvate, glucose, glutamine
and amphotericin. The medium was enriched for plating
with 2% of fetal calf serum (v/v). The medium was
exchanged for a serum-free medium the next day and
the culture was stabilized for additional 24 h. After that
the cells were ready for the treatment. The cultures were
maintained at 37°C and 5% CO2 in a humidified
incubator.
THP-1 cell culture and differentiation to macrophages
To determine the influence of the tested complexes on
the TNF-α and IL-1β secretions, the human monocytic
leukemia cell line THP-1 was used. The cells were culti-
vated at 37°C in the RPMI 1640 medium supplemented
with 2 mM L-glutamine, 10% fetal bovine serum (FBS),
100 U/mL of penicillin and 100 μg/mL of streptomycinin a humidified atmosphere containing 5% CO2. The sta-
bilized cells (3rd–20th passage) were split into microti-
tration plates to get a concentration of 100 000 cells/mL
and the differentiation to macrophages was induced by a
phorbol myristate acetate (PMA) as we described previ-
ously [40].
Drug treatment and induction of inflammatory response
Differentiated macrophages were pretreated for 1 h with
0.2 μM solutions of the tested complexes, prednisone or
CuSO4 · 5 H2O dissolved in DMSO (the final DMSO
concentration was 0.1%) and with 0.1% DMSO solution
itself (the experimental group called vehicle); the given
concentrations of the tested compounds lack the cyto-
toxic effect. The inflammatory response was triggered by
adding 1.0 μg/mL lipopolysaccharide (LPS) dissolved in
water to pretreated macrophages, control cells were with-
out the LPS treatment. Each experiment was repeated
three-times [38].
Evaluation of cytokine secretion by ELISA
Macrophages pretreated with the tested compounds for
1 h were incubated with LPS for next 24 h. After this
period, the medium was collected and the concentration
of TNF-α and IL-1β was measured by Instant ELISA kit
(eBioscience, Vienna, Austria) according to the manufac-
turer’s manual.
Gene reporter assays
The transcriptional activity of AhR was assessed using
the human hepatoma cells HepG2 stably transfected
with plasmid containing dioxin-response elements fused
to the luciferase reporter gene (AZ-AhR cells). The con-
struction and characterization of the AZ-AhR cell line
was described elsewhere [22]. The transcriptional activity
of GR was assessed in human cervix carcinoma cells HeLa
stably transfected with plasmid containing glucocorticoid-
response elements fused to the luciferase reporter gene
(AZ-GR cells). The cells were seeded in the medium sup-
plemented with 10% charcoal/dextran-stripped foetal bo-
vine serum on 96-well plates and stabilized for 16 h prior
to the treatments. The cells were treated for 24 h with the
tested compounds, TCDD (5 nM), dexamethasone
(100 nM) and/or vehicle (DMSO; 0.1%, v/v). After the
treatments, the cells were lysed using a luciferase detec-
tion system (Promega) and the luciferase activity was mea-
sured on a luminometer (Tecan, Schoeller, Prague).
Interactions of complexes 1, 3 and 5 with cysteine and
glutathione assessed by electrospray-ionization mass
spectrometry
The electrospray-ionization mass spectrometry (ESI-MS)
is a widely used method for studies of covalent [41] or
non-covalent [42,43] interactions of small molecules or
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performed the interaction experiments between com-
plexes 1–6 and cysteine or glutathione respectively on
an Agilent HP1100 LC-MSD VL Ion-Trap mass spec-
trometer, using the positive ionization mode. The para-
meters set for the analyses were as follows: the
measured solutions were infused directly to the spray-
needle by linear pump with the rate of 2000 μL/h, the
nebulization gas (nitrogen) flow was set to 6 L/min and
its pressure was 60 psi. The drying gas temperature was
set to 250°C. The measured range of ions was set from
m/z 50 to 1500. Before the analysis of the interacting
systems, the instrument parameter set (such as skimmer
voltages, trap drive, octopole RF amplitude, octopole
delta, lenses voltages, capillary voltage, etc.) was auto-
matically optimized for the ion m/z 308 ± 0.5, corre-
sponding to the protonized form of reduced glutathione
(m/z 308 ± 0.5; GSH +H+).
Additional file
Additional file 1: Figure S1-S8. The Additional file 1 contains graphical
representations of the results of in vitro cytotoxicity testing (Figs. S1–S8).
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